Physician profile
Louisa Vikner
NPI 1104356385
$1,575.65
in general payments reported to CMS, 2019-2025
25 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.81 · 2022: $443 · 2023: $342 · 2024: $339 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $417.32 | 2021-2025 | |
| Astellas Pharma US INC | $225.98 | 2022-2025 | Veozah |
| Exeltis, USA INC. | $124.26 | 2021-2025 | Slynd, Tyblume |
| Abbvie INC. | $97.50 | 2022-2023 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $92.84 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $67.40 | 2022-2025 | Evenity |
| Myovant Sciences INC. | $63.34 | 2022 | |
| Becton, Dickinson and Company | $53.86 | 2024 | Bd Onclarity |
| Avion Pharmaceuticals | $53.35 | 2021-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $33.37 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $30.98 | 2024-2025 | Zurzuvae |
| Organon LLC | $30.90 | 2024 | |
| Myriad Women'S Health, INC. | $30.36 | 2023 | Myrisk |
| Agile Therapeutics, INC. | $30.11 | 2022 | |
| Mimedx Group, INC. | $29.86 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $29.83 | 2021-2022 | |
| Scynexis, INC. | $28.66 | 2022 | |
| Pfizer INC. | $26.91 | 2024 | |
| Dysis Medical, INC. | $17.69 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.00 | 2025 | Qelbree |
| Mycovia Pharmaceuticals, INC. | $15.48 | 2023 | Vivjoa |
| Coopersurgical, INC. | $15.40 | 2024 | Paragard T 380a |
| Pacira Pharmaceuticals Incorporated | $14.97 | 2024 | Exparel |
| Cook Medical LLC | $14.23 | 2021 | |
| Daiichi Sankyo INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louisa Vikner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.